Cogent Biosciences, Inc. (COGT)
36.23
-0.50
(-1.36%)
USD |
NASDAQ |
Aug 24, 16:00
36.23
0.00 (0.00%)
After-Hours: 20:00
Cogent Biosciences Enterprise Value : 5.821B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 5.821B |
| August 20, 2026 | 5.577B |
| August 19, 2026 | 5.842B |
| August 18, 2026 | 5.936B |
| August 17, 2026 | 6.017B |
| August 14, 2026 | 6.027B |
| August 13, 2026 | 5.921B |
| August 12, 2026 | 6.207B |
| August 11, 2026 | 6.159B |
| August 10, 2026 | 6.645B |
| August 07, 2026 | 6.793B |
| August 06, 2026 | 6.691B |
| August 05, 2026 | 6.772B |
| August 04, 2026 | 6.870B |
| August 03, 2026 | 6.187B |
| July 31, 2026 | 6.199B |
| July 30, 2026 | 6.616B |
| July 29, 2026 | 6.309B |
| July 28, 2026 | 6.497B |
| July 27, 2026 | 6.458B |
| July 24, 2026 | 6.341B |
| July 23, 2026 | 6.424B |
| July 22, 2026 | 6.303B |
| July 21, 2026 | 6.321B |
| July 20, 2026 | 6.091B |
| Date | Value |
|---|---|
| July 17, 2026 | 6.224B |
| July 16, 2026 | 6.029B |
| July 15, 2026 | 6.262B |
| July 14, 2026 | 6.127B |
| July 13, 2026 | 5.946B |
| July 10, 2026 | 6.188B |
| July 09, 2026 | 6.470B |
| July 08, 2026 | 6.377B |
| July 07, 2026 | 6.384B |
| July 06, 2026 | 6.286B |
| July 02, 2026 | 6.158B |
| July 01, 2026 | 6.122B |
| June 30, 2026 | 6.159B |
| June 29, 2026 | 6.055B |
| June 26, 2026 | 5.945B |
| June 25, 2026 | 5.930B |
| June 24, 2026 | 5.848B |
| June 23, 2026 | 5.639B |
| June 22, 2026 | 5.559B |
| June 18, 2026 | 5.337B |
| June 17, 2026 | 5.188B |
| June 16, 2026 | 5.086B |
| June 15, 2026 | 5.103B |
| June 12, 2026 | 5.091B |
| June 11, 2026 | 5.009B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Apogee Therapeutics, Inc. | 9.286B |
| ImmunityBio, Inc. | 9.076B |
| Erasca, Inc. | 5.286B |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Oncolytics Biotech, Inc. | 101.41M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -96.40M |
| Total Expenses (Quarterly) | 96.40M |
| EPS Diluted (Quarterly) | -0.5636 |
| Earnings Yield | -6.75% |
| Normalized Earnings Yield | -6.655 |